Jeremy Grantham's RNA Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 154,455 shares of Avidity Biosciences, Inc. (RNA) worth $11.14 M, representing 0.03% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jeremy Grantham has initiated a new position in RNA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Avidity Biosciences (RNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Avidity Biosciences (RNA) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +154,455 | New Buy | 154,455 | $72.13 |
Jeremy Grantham's Avidity Biosciences Investment FAQs
Jeremy Grantham first purchased Avidity Biosciences, Inc. (RNA) in Q4 2025, acquiring 154,455 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Avidity Biosciences, Inc. (RNA) for 1 quarters since Q4 2025.
Jeremy Grantham's largest addition to Avidity Biosciences, Inc. (RNA) was in Q4 2025, adding 154,455 shares worth $11.14 M.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 154,455 shares of Avidity Biosciences, Inc. (RNA), valued at approximately $11.14 M.
As of the Q4 2025 filing, Avidity Biosciences, Inc. (RNA) represents approximately 0.03% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Avidity Biosciences, Inc. (RNA) was 154,455 shares, as reported at the end of Q4 2025.